8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 3, 2026·SEC
Denali Therapeutics Inc.(DNLI)Earnings, Financials & Key Ratios
DNLI•NASDAQ
Price updated Jun 19, 2026
AboutDenali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$541M-13.0%
- Net Income-$513M-21.2%
- EPS (Diluted)-2.97-15.6%
- ROE-45.69%-22.2%
DNLI Key Insights
Denali Therapeutics Inc. (DNLI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 82 (top 18%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when DNLI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DNLI Price & Volume
Denali Therapeutics Inc. (DNLI) stock price & volume — 10-year historical chart
Loading chart...
DNLI Growth Metrics
Denali Therapeutics Inc. (DNLI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-11.91%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-7.87%
Return on Capital
10 Years-28.63%
5 Years-32.55%
3 Years-35.84%
Last Year-47.91%
DNLI Recent Earnings
Denali Therapeutics Inc. (DNLI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 1/12 qtrs (50%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.69+5.5%
$0.73
Rev
—
$3M
Q2 2026
May 5, 2026Metric
Actual
Est
EPS
$0.69+5.5%
$0.73
Rev
—
$3M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.73+2.7%
$0.75
Rev
—
$3M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.74+2.6%
$0.76
Rev
—
$3M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.69vs $0.73+5.5% | —vs $3M |
| Q2 2026 | May 5, 2026 | $0.69vs $0.73+5.5% | —vs $3M |
| Q1 2026 | Feb 26, 2026 | $0.73vs $0.75+2.7% | —vs $3M |
| Q4 2025 | Nov 6, 2025 | $0.74vs $0.76+2.6% | —vs $3M |
Based on last 12 quarters of dataView full earnings history →
DNLI Peer Comparison
Denali Therapeutics Inc. (DNLI) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ARVN | 494.88M | 7.67 | -5.99 | -0.3% | -247.54% | -44.39% | 0.02 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PTGX | 7.26B | 112.86 | -55.05 | -89.41% | -6.48% | -17.76% | 0.02 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 |
Compare DNLI vs Peers
Denali Therapeutics Inc. (DNLI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DNLI Income Statement
Denali Therapeutics Inc. (DNLI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 129.16M | 26.68M | 335.66M | 48.66M | 108.46M | 330.53M | 0 | 0 | 0 |
Revenue Growth % | - | - | -79.34% | 1158.19% | -85.5% | 122.9% | 204.74% | -100% | - | - |
Cost of Goods Sold | 3.08M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.18M | 5.71M |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -3.08M▲ 0% | 129.16M▲ 4290.8% | 26.68M▼ 79.3% | 335.66M▲ 1158.2% | 48.66M▼ 85.5% | 108.46M▲ 122.9% | 330.53M▲ 204.7% | 0▼ 100.0% | -11.18M▲ 0% | -5.71M▲ 0% |
Gross Margin % | - | 100% | 100% | 100% | 100% | 100% | 100% | - | - | - |
Gross Profit Growth % | -109.8% | 4290.79% | -79.34% | 1158.19% | -85.5% | 122.9% | 204.74% | -100% | - | - |
Operating Expenses | 90.14M | 175.53M | 239.86M | 272.94M | 344.41M | 449.21M | 527.23M | 487.34M | 544.16M | 541.41M |
OpEx % of Revenue | - | 135.9% | 899.1% | 81.31% | 707.78% | 414.16% | 159.51% | - | - | - |
Selling, General & Admin | 15.68M | 32.35M | 46.48M | 60.33M | 79.06M | 90.47M | 103.35M | 105.44M | 97.1M | 135.01M |
SG&A % of Revenue | - | 25.05% | 174.23% | 17.97% | 162.47% | 83.42% | 31.27% | - | - | - |
Research & Development | 74.46M | 143.18M | 193.38M | 212.62M | 265.35M | 358.73M | 423.88M | 396.44M | 418.78M | 406.4M |
R&D % of Revenue | - | 110.86% | 724.87% | 63.34% | 545.31% | 330.74% | 128.24% | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -14.54M | 28.28M | 0 |
Operating Income | -90.14M▲ 0% | -46.37M▲ 48.6% | -213.18M▼ 359.7% | 62.72M▲ 129.4% | -295.75M▼ 571.6% | -340.74M▼ 15.2% | -196.7M▲ 42.3% | -487.34M▼ 147.8% | -555.34M▼ 14.0% | -547.12M▲ 0% |
Operating Margin % | - | -35.9% | -799.1% | 18.68% | -607.78% | -314.16% | -59.51% | - | - | - |
Operating Income Growth % | -3.1% | 48.56% | -359.73% | 129.42% | -571.56% | -15.21% | 42.27% | -147.76% | -13.95% | - |
EBITDA | -87.06M | -38.96M | -205.19M | 71.25M | -287.16M | -330.36M | -179.97M | -478.35M | -540.53M | -532.67M |
EBITDA Margin % | - | -30.16% | -769.15% | 21.23% | -590.12% | -304.58% | -54.45% | - | - | - |
EBITDA Growth % | -1.27% | 55.25% | -426.72% | 134.72% | -503.03% | -15.04% | 45.52% | -165.79% | -13% | -5.45% |
D&A (Non-Cash Add-back) | 3.08M | 7.42M | 7.99M | 8.53M | 8.59M | 10.38M | 16.73M | 8.99M | 14.81M | 14.45M |
EBIT | -90.14M | -46.37M | -213.18M | 62.72M | -295.75M | -340.74M | -196.7M | -501.88M | -512.44M | -538.2M |
Net Interest Income | 0 | 10.13M | 15.22M | 9.24M | 4.59M | 14.77M | 51.51M | 64.64M | 42.9M | 39.2M |
Interest Income | 1.96M | 10.13M | 15.22M | 9.24M | 4.59M | 14.77M | 51.51M | 64.64M | 42.9M | 39.2M |
Interest Expense | 1.96M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 1.96M | 10.13M | 15.22M | 9.24M | 4.59M | 14.77M | 51.51M | 64.64M | 42.9M | 39.2M |
Pretax Income | -88.19M▲ 0% | -36.24M▲ 58.9% | -197.97M▼ 446.3% | 71.96M▲ 136.3% | -291.16M▼ 504.6% | -325.97M▼ 12.0% | -145.19M▲ 55.5% | -422.7M▼ 191.1% | -512.44M▼ 21.2% | -507.92M▲ 0% |
Pretax Margin % | - | -28.06% | -742.05% | 21.44% | -598.34% | -300.54% | -43.93% | - | - | - |
Income Tax | 0 | 0 | -351K | 823K | -575K | 21K | 30K | 68K | 102K | 102K |
Effective Tax Rate % | 0% | 0% | 0.18% | 1.14% | 0.2% | -0.01% | -0.02% | -0.02% | -0.02% | -0.02% |
Net Income | -88.19M▲ 0% | -36.24M▲ 58.9% | -197.61M▼ 445.3% | 71.14M▲ 136.0% | -290.58M▼ 508.5% | -325.99M▼ 12.2% | -145.22M▲ 55.5% | -422.77M▼ 191.1% | -512.54M▼ 21.2% | -508.02M▲ 0% |
Net Margin % | - | -28.06% | -740.74% | 21.19% | -597.15% | -300.56% | -43.94% | - | - | - |
Net Income Growth % | -1.77% | 58.9% | -445.29% | 136% | -508.49% | -12.19% | 55.45% | -191.12% | -21.23% | -11.91% |
Net Income (Continuing) | -88.19M | -36.24M | -197.61M | 71.14M | -290.58M | -325.99M | -145.22M | -422.77M | -512.54M | -508.02M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -5.89▲ 0% | -0.39▲ 93.4% | -2.07▼ 430.8% | 0.63▲ 130.4% | -2.39▼ 479.4% | -2.60▼ 8.8% | -1.06▲ 59.2% | -2.57▼ 142.5% | -2.97▼ 15.6% | -2.72▲ 0% |
EPS Growth % | 56.34% | 93.38% | -430.77% | 130.43% | -479.37% | -8.79% | 59.23% | -142.45% | -15.56% | -7.87% |
EPS (Basic) | -5.89 | -0.39 | -2.07 | 0.65 | -2.39 | -2.60 | -1.06 | -2.57 | -2.97 | - |
Diluted Shares Outstanding | 14.96M | 92.62M | 95.61M | 112.7M | 121.52M | 125.53M | 137.37M | 164.47M | 175.46M | 186.64M |
Basic Shares Outstanding | 14.96M | 92.62M | 95.61M | 108.97M | 121.52M | 125.53M | 137.37M | 164.47M | 175.46M | 186.64M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
DNLI Balance Sheet
Denali Therapeutics Inc. (DNLI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 409.61M | 480.84M | 430.03M | 1.5B | 897.23M | 1.37B | 1.06B | 864.44M | 900.66M | 1.02B |
Cash & Short-Term Investments | 406.23M | 464.3M | 415.36M | 1.47B | 865.41M | 1.34B | 1.03B | 832.33M | 867.88M | 987.68M |
Cash Only | 218.38M | 77.12M | 79.45M | 507.14M | 293.48M | 218.04M | 127.11M | 174.96M | 205.33M | 387.63M |
Short-Term Investments | 187.85M | 387.17M | 335.91M | 962.55M | 571.93M | 1.12B | 907.4M | 657.37M | 662.55M | 600.06M |
Accounts Receivable | 464K | 8.55M | 0 | 0 | 1.23M | 9.28M | 3.42M | 2.17M | 2.18M | 1.6M |
Days Sales Outstanding | - | 24.15 | - | - | 9.2 | 31.24 | 3.78 | - | - | - |
Inventory | -464K | -8.55M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 1.35M | 0 | 25.96M | 0 | 0 | 0 | 0 | 30.6M | 33.47M |
Total Non-Current Assets | 77.11M | 181.15M | 123.2M | 108.63M | 506.93M | 87.92M | 89.78M | 509.74M | 244.2M | 243.27M |
Property, Plant & Equipment | 14.92M | 25.16M | 80.66M | 73.46M | 69.61M | 74.52M | 71.64M | 125.63M | 119.94M | 117.27M |
Fixed Asset Turnover | - | 5.13x | 0.33x | 4.57x | 0.70x | 1.46x | 4.61x | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 36M |
Long-Term Investments | 60.75M | 147.88M | 39.89M | 34.2M | 425.45M | 0 | 0 | 359.37M | 0 | 274.57M |
Other Non-Current Assets | 1.44M | 8.11M | 2.66M | 962K | 11.87M | 13.4M | 18.14M | 24.74M | 124.26M | 23.12M |
Total Assets | 486.72M▲ 0% | 661.98M▲ 36.0% | 553.23M▼ 16.4% | 1.6B▲ 190.0% | 1.4B▼ 12.5% | 1.46B▲ 4.0% | 1.15B▼ 21.0% | 1.37B▲ 19.1% | 1.14B▼ 16.7% | 1.27B▲ 0% |
Asset Turnover | - | 0.20x | 0.05x | 0.21x | 0.03x | 0.07x | 0.29x | - | - | 0.00x |
Asset Growth % | 79.56% | 36.01% | -16.43% | 189.98% | -12.47% | 3.99% | -20.98% | 19.09% | -16.69% | -66.89% |
Total Current Liabilities | 14.16M | 32.79M | 45.34M | 71.7M | 378.25M | 363.92M | 77.98M | 102.21M | 98.35M | 110.16M |
Accounts Payable | 2.72M | 1.89M | 2.59M | 1.07M | 4.78M | 2.79M | 9.48M | 11.14M | 3.33M | 40.38M |
Days Payables Outstanding | 321.65 | - | - | - | - | - | - | - | 108.69 | 979.43 |
Short-Term Debt | 0 | 0 | 0 | 4.69M | 0 | 0 | 0 | 0 | 9.55M | 9.86M |
Deferred Revenue (Current) | 0 | 11.43M | 18.74M | 23.48M | 320.3M | 290.05M | 0 | 0 | 0 | 37.7M |
Other Current Liabilities | 918K | 9.52M | 8.74M | 21.95M | 19.01M | 17.09M | 21.59M | 38.86M | 85.47M | 35.58M |
Current Ratio | 28.92x | 14.67x | 9.48x | 20.86x | 2.37x | 3.77x | 13.65x | 8.46x | 9.16x | 9.28x |
Quick Ratio | 28.95x | 14.93x | 9.48x | 20.86x | 2.37x | 3.77x | 13.65x | 8.46x | 9.16x | 9.28x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 6.76M | 82.35M | 113M | 382.05M | 63.63M | 53.89M | 44.98M | 42.29M | 32.74M | 229.77M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 68.86M | 64.17M | 58.55M | 53.03M | 44.98M | 36.67M | 32.74M | 135.86M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6.76M | 25M | 379K | 701K | 379K | 379K | 0 | 5.62M | 0 | 0 |
Total Liabilities | 20.93M | 115.14M | 158.34M | 453.75M | 441.87M | 417.81M | 122.96M | 144.5M | 131.09M | 339.93M |
Total Debt | 0 | 0 | 72.53M | 68.86M | 64.01M | 60.35M | 52.24M | 48.71M | 42.29M | 40.05M |
Net Debt | -218.38M | -77.12M | -6.92M | -438.28M | -229.47M | -157.69M | -74.86M | -126.25M | -163.04M | -347.58M |
Debt / Equity | - | - | 0.18x | 0.06x | 0.07x | 0.06x | 0.05x | 0.04x | 0.04x | 0.04x |
Debt / EBITDA | - | - | - | 0.97x | - | - | - | - | - | -0.08x |
Net Debt / EBITDA | - | - | - | -6.15x | - | - | - | - | - | 0.65x |
Interest Coverage | -46.11x | - | - | - | - | - | - | - | - | - |
Total Equity | 465.8M▲ 0% | 546.85M▲ 17.4% | 394.89M▼ 27.8% | 1.15B▲ 191.4% | 962.29M▼ 16.4% | 1.04B▲ 8.3% | 1.03B▼ 1.1% | 1.23B▲ 19.3% | 1.01B▼ 17.6% | 926.1M▲ 0% |
Equity Growth % | 83.01% | 17.4% | -27.79% | 191.35% | -16.36% | 8.33% | -1.1% | 19.28% | -17.56% | -90.78% |
Book Value per Share | 31.13 | 5.90 | 4.13 | 10.21 | 7.92 | 8.30 | 7.50 | 7.48 | 5.78 | 4.96 |
Total Shareholders' Equity | 465.8M | 546.85M | 394.89M | 1.15B | 962.29M | 1.04B | 1.03B | 1.23B | 1.01B | 926.1M |
Common Stock | 1.2M | 1.27M | 1.29M | 1.53M | 1.55M | 1.69M | 1.71M | 1.77M | 1.89M | 1.91M |
Retained Earnings | -191.7M | -227.94M | -425.55M | -354.42M | -645M | -970.99M | -1.12B | -1.54B | -2.05B | -2.18B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -368K | -649K | 350K | -245K | -2.5M | -6.89M | 643K | 2.02M | 682K | -682K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DNLI Cash Flow Statement
Denali Therapeutics Inc. (DNLI) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -76.64M | 50.12M | -151.58M | 416.15M | -211.39M | -244.72M | -357.99M | -347.69M | -412.6M | -412.34M |
Operating CF Margin % | - | 38.8% | -568.17% | 123.98% | -434.41% | -225.62% | -108.31% | - | - | - |
Operating CF Growth % | -5.91% | 165.4% | -402.45% | 374.55% | -150.8% | -15.77% | -46.29% | 2.88% | -18.67% | -81.48% |
Net Income | -88.19M | -36.24M | -197.61M | 71.14M | -290.58M | -325.99M | -145.22M | -422.77M | -512.54M | -508.02M |
Depreciation & Amortization | 3.08M | 7.42M | 7.99M | 8.53M | 8.59M | 10.38M | 16.73M | 8.99M | 14.81M | 13.54M |
Stock-Based Compensation | 4.41M | 18.79M | 38.38M | 50.35M | 85.25M | 99.85M | 108.1M | 102.88M | 99.63M | 47.04M |
Deferred Taxes | 0 | 0 | 0 | 55K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 754K | -2.74M | -3.25M | -2.32M | 5.76M | -4.92M | -47.67M | -53.73M | -14.65M | 40.52M |
Working Capital Changes | 3.31M | 62.89M | 2.92M | 288.4M | -20.41M | -24.03M | -289.93M | 16.94M | 149K | -5.41M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 207K | -526K | 1.03M | -1.62M | 3.71M | 2.27M | 2.43M | 1.44M | -7.52M | -1.01M |
Cash from Investing | -41.17M | -287.42M | 147.71M | -623.21M | -21.63M | -141.39M | 249.31M | -88.76M | 255.28M | 330.99M |
Capital Expenditures | -2.88M | -3.39M | -17.92M | -3.1M | -8.5M | -17.83M | -12.94M | -15.91M | -9.5M | -6.89M |
CapEx % of Revenue | - | 2.63% | 67.17% | 0.92% | 17.47% | 16.44% | 3.91% | - | - | - |
Acquisitions | 0 | 0 | 0 | 620.11M | 0 | 123.55M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -38.29M | -284.03M | 0 | -620.11M | 0 | -123.55M | 0 | 0 | 0 | 0 |
Cash from Financing | 296.32M | 97.02M | 6.19M | 634.75M | 19.35M | 310.67M | 17.82M | 484.3M | 189.22M | 412.02M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -32.34M | -8.17M | -3.83M |
Equity Issued (Net) | 295.59M | 94.41M | 0 | 614.09M | 0 | 296.21M | 17.82M | 499.25M | 197.38M | 215.85M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 733K | 2.61M | 6.19M | 20.66M | 19.35M | 14.46M | 0 | 17.39M | 0 | 200M |
Net Change in Cash | 178.52M▲ 0% | -140.29M▼ 178.6% | 2.33M▲ 101.7% | 427.69M▲ 18287.6% | -213.67M▼ 150.0% | -75.43M▲ 64.7% | -90.94M▼ 20.6% | 47.85M▲ 152.6% | 31.9M▼ 33.3% | 330.68M▲ 0% |
Free Cash Flow | -79.51M▲ 0% | 46.72M▲ 158.8% | -169.5M▼ 462.8% | 413.06M▲ 343.7% | -219.89M▼ 153.2% | -262.55M▼ 19.4% | -370.93M▼ 41.3% | -363.61M▲ 2.0% | -422.1M▼ 16.1% | -419.23M▲ 0% |
FCF Margin % | - | 36.17% | -635.34% | 123.06% | -451.88% | -242.06% | -112.22% | - | - | - |
FCF Growth % | -1.3% | 158.76% | -462.77% | 343.7% | -153.23% | -19.4% | -41.28% | 1.97% | -16.09% | -9.06% |
FCF per Share | -5.31 | 0.50 | -1.77 | 3.67 | -1.81 | -2.09 | -2.70 | -2.21 | -2.41 | -2.25 |
FCF Conversion (FCF/Net Income) | 0.87x | -1.38x | 0.77x | 5.85x | 0.73x | 0.75x | 2.47x | 0.82x | 0.81x | 0.83x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 210K | 47K | 0 | 0 | 0 | 0 |
DNLI Key Ratios
Denali Therapeutics Inc. (DNLI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -24.49% | -7.16% | -41.97% | 9.21% | -27.51% | -32.52% | -14.01% | -37.4% | -45.69% | -52.2% |
Return on Invested Capital (ROIC) | -29.26% | -9.7% | -37.28% | 8.55% | -30.7% | -31.6% | -16.03% | -35.49% | -42.63% | -50.64% |
Gross Margin | - | 100% | 100% | 100% | 100% | 100% | 100% | - | - | - |
Net Margin | - | -28.06% | -740.74% | 21.19% | -597.15% | -300.56% | -43.94% | - | - | - |
Debt / Equity | - | - | 0.18x | 0.06x | 0.07x | 0.06x | 0.05x | 0.04x | 0.04x | 0.04x |
Interest Coverage | -46.11x | - | - | - | - | - | - | - | - | - |
FCF Conversion | 0.87x | -1.38x | 0.77x | 5.85x | 0.73x | 0.75x | 2.47x | 0.82x | 0.81x | 0.83x |
Revenue Growth | - | - | -79.34% | 1158.19% | -85.5% | 122.9% | 204.74% | -100% | - | - |
Related:DNLI Dividend History·DNLI Revenue History·DNLI Price History·DNLI P/E History·DNLI Financial Ratios·DNLI Institutional Holders
DNLI SEC Filings & Documents
Denali Therapeutics Inc. (DNLI) SEC filings — annual & quarterly reports (10-K, 10-Q)
DNLI Frequently Asked Questions
Denali Therapeutics Inc. (DNLI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Denali Therapeutics Inc. (DNLI) grew revenue by 0.0% over the past year. Growth has been modest.
Denali Therapeutics Inc. (DNLI) reported a net loss of $508.0M for fiscal year 2025.
Dividend & Returns
Denali Therapeutics Inc. (DNLI) has a return on equity (ROE) of -45.7%. Negative ROE indicates the company is unprofitable.
Denali Therapeutics Inc. (DNLI) had negative free cash flow of $419.2M in fiscal year 2025, likely due to heavy capital investments.